Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 75.
STALEVO 100 vs STALEVO 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
STALEVO 75 is a combination product containing carbidopa, levodopa, and entacapone. Levodopa is the metabolic precursor of dopamine, which crosses the blood-brain barrier and is converted to dopamine in the brain, thereby ameliorating dopamine deficiency in Parkinson's disease. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which prolongs the plasma half-life of levodopa.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
Oral, 1 tablet (levodopa 75 mg, carbidopa 18.75 mg, entacapone 200 mg) taken 3 to 4 times daily. Maximum recommended dose: 10 tablets per day (levodopa 750 mg, carbidopa 187.5 mg, entacapone 2000 mg). Dose should be adjusted based on individual response and tolerability.
None Documented
None Documented
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Levodopa: 1.5-2 hours (alone). With carbidopa: 1.5 hours. Entacapone: 0.4-0.7 hours (elimination half-life). Clinical context: Entacapone prolongs levodopa half-life by ~30% via COMT inhibition.
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Carbidopa: 70% renal (metabolites), 30% fecal. Levodopa: 80% renal (metabolites), 20% fecal. Entacapone: 90% fecal, 10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent